Merck & Co. Inc (6MK DU) stock market data APIs
€68.896
0.26(0.4%)
as of July 4, 2025
Try our APIs with
free plan!
Merck & Co. Inc Financial Data Overview
Price chart is built with
Anychart
There is no Profile data available for 6MK.DU.
Prev. Close
68.896
Open
69.1552
High
68.896
Low
69.1552
52 wk Range
64.8498-115.459
Market Cap
162 424 M
Dividends (Yield)
0.0233
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Merck & Co. Inc data using free add-ons & libraries
Get Merck & Co. Inc Fundamental Data
Merck & Co. Inc Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: NaN
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Merck & Co. Inc News
New
FDA Grants Priority Review for Merck & Co’s (MRK) WINREVAIR
Merck & Co., Inc. (NYSE:MRK) is one of the 10 Best Dip Stocks to Buy According to Billionaires. On July 2, Merck & Co., Inc. (NYSE:MRK) announced that the FDA has accepted and granted priority review ...
Merck & Co (MRK) Announces the Approval of ENFLONSIA
Merck & Co., Inc. (NYSE:MRK) is one of the 11 Best 52-Week Low Stocks to Buy Right Now.On June 26, Merck & Co., Inc. (NYSE:MRK) announced that the Advisory Committee on Immunization Practices has appr...
Top Dividend Stocks To Consider In July 2025
Over the last 7 days, the United States market has risen 2.1%, contributing to a notable 14% climb over the past year, with earnings expected to grow by 15% annually. In this favorable environment, id...
Will Novo Nordisk's Rare Disease Bets Reduce GLP-1 Reliance?
Novo Nordisk NVO has experienced remarkable growth in recent years, largely fueled by the commercial success of its blockbuster semaglutide (GLP-1 RA)-based therapies, Wegovy for obesity and Ozempic f...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
